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STUDY QUESTION: Does adrenocorticotropic hormone (ACTH) induce gonadotropin release in premenopausal women?
SUMMARY ANSWER: Administration of ACTH stimulates gonadotropin release, most likely by stimulation of the production of cortisol,
in premenopausal women.
WHAT IS KNOWN ALREADY: In animal models, acute activation of the hypothalamic-pituitary-adrenal (HPA) axis has been shown to
induce gonadotropin release in the presence of sufﬁciently high estrogen levels. However, it is unknown whether the HPA axis has a similar
inﬂuence on gonadotropin release in humans.
STUDY DESIGN, SIZE, DURATION: This study had a mixed factorial design. A total of 60 healthy female participants participated in the
experimental study.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The study sample comprised three distinct hormonal-based populations
according to their levels of progesterone (PROG) and estradiol (E2): (i) low-PROG–low-E2, (ii) low-PROG–high-E2 and (iii) high-PROG–
high-E2 women. A low dose (1 µg) of ACTH was administered to all study participants. Serum steroid and gonadotropin concentrations
were measured prior to, and at 30 and 90 minutes after, intravenous ACTH administration.
MAIN RESULTS AND THE ROLE OF CHANCE: Mean serum cortisol levels increased signiﬁcantly following ACTH administration in
all groups (P < 0.001). Similarly, the serum levels of 17-OH-PROG, androstenedione, dehydroepiandrosterone and testosterone increased
signiﬁcantly in all groups (P < 0.01). The low-PROG–high-E2 and high-PROG–high-E2 groups exhibited a signiﬁcant increase in LH and FSH
levels (P < 0.001), whereas the low-PROG–low-E2 group demonstrated blunted LH and FSH responses to ACTH administration (P < 0.05).
LIMITATIONS, REASONS FOR CAUTION: Testing was performed during the luteal phase of the natural menstrual cycle. Testing during
the follicular phase might have elicited premature, or more pronounced, LH surges in response to ACTH administration.
WIDER IMPLICATIONS OF THE FINDINGS: Our ﬁndings suggest a novel mechanism by which the adrenal cortex functions as a medi-
ator of gonadotropin release. These ﬁndings contribute to a greater understanding of the inﬂuence of acute stress on reproductive
endocrinology.
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Introduction
Psychosocial stress is a highly signiﬁcant factor predicting health out-
comes and quality of life (Sapolsky, 2005). The best-studied physio-
logical response to stress is mediated by the hypothalamic-pituitary-
adrenal (HPA) axis, which can be affected by the hypothalamic-pituit-
ary-gonadal axis, regulating metabolism and reproductive function,
respectively (Viau, 2002; Handa and Weiser, 2014). Previous studies
have also demonstrated that chronic persistent stress interferes with
the release of hypothalamic gonadotropin-releasing hormone (GnRH),
resulting in a suppression of gonadotropin levels (Brann and Mahesh,
1991; Whirledge and Cidlowski, 2013). Studies in animal models have
elucidated candidate physiological mechanisms underlying the well-
replicated ﬁnding of stress-induced reproductive suppression in
humans (Riviera and Rivest, 1991; Tilbrook et al., 2000; Wingﬁeld and
Sapolsky, 2003). The female reproductive system is powerfully modu-
lated by stress, often leading to chronic anovulation and amenorrhea
during periods of persistent stress (Warren and Perlroth, 2001). In
adolescents, chronic stress has been shown to signiﬁcantly delay the
onset of puberty (Magner et al., 1984).
Contrary to the effects of persistent stress, acute stress has been
repeatedly shown to facilitate reproductive functioning by stimulating
gonadotropin secretion (Brann and Mahesh, 1991; Brann et al., 1991).
Animal studies have yielded a candidate hormonal mechanism through
which acute stressors facilitate the release of luteinizing hormone (LH)
and follicle stimulating hormone (FSH) (Putnam et al., 1991). Notably,
the effect of acute stress on gonadotropin release is highly dependent
upon the circulating level of estradiol (Putnam et al., 1991; Puder et al.,
2000; Micevych et al., 2008). Moreover, adrenalectomy, but not ovari-
ectomy, abolishes the facilitation of gonadotropin release by acute
stress in rodents (Mahesh and Brann, 1998; Puder et al., 2000). Finally,
adrenal PROG has been implicated as an important mediator of the
stimulatory effect of stress on gonadotropins in the presence of an
estrogen-primed environment (Putnam et al., 1991; Xiao et al., 1994).
Taken together, widely convergent evidence in animal studies has given
considerable support to the hypothesis that the facilitation of gonado-
tropin release by acute stress is mediated through adrenal steroids.
To date, studies regarding the effects of HPA-axis stimulation on LH
release in humans have concluded that in postmenopausal women, the
LH response to adrenal stimulation is highly estrogen-dependent
(Puder et al., 2000), and signiﬁcantly potentiated by PROG (Cano and
Tarín, 1998). However, it remains unknown whether gonadotropin
release is facilitated by adrenal stimulation in premenopausal women
and the extent to which this may be governed by ovarian function.
Therefore, the aim of this study was to determine the inﬂuence of
acute adrenocortical stimulation by administration of a low dose of
ACTH on the release of LH and FSH in women with a normal men-
strual cycle. In addition, we sought to explore the modulatory effect of
estrogen and progestin on adrenal facilitation of gonadotropin release
by administering a low dose of ACTH in three distinct healthy popula-
tions: (i) women having a natural menstrual cycle, (ii) women taking
oral contraceptive pills (a combination of estrogen/progestin) and (iii)
women using a progestin-releasing intrauterine device (IUD).
Combination estrogen/progestin contraceptives have previously been
shown to inhibit ovarian function (Amy and Tripathi, 2009; Benagiano
et al., 2009). In comparison, the progestin-releasing IUD has been sug-
gested to, only partly and only during the ﬁrst year, inhibit ovarian
function, leaving circulating estradiol within the normal range for
women of reproductive age (Barbosa et al., 1990; Lähteenmäki et al.,
2000). Considering that levonorgestrel-releasing IUD (LNG-IUD)
does not generally excrete sufﬁcient amounts of progesterone to sup-
press the hypothalamic ovarian axis (Apter et al., 2014), and given the
possibility of a difference in gonadotropin release between young pre-
menopausal women in the preovulatory versus postovulatory phase,
we reclassiﬁed the groups based on PROG level and ovulatory phase.
This study design provided us with the opportunity to compare the
effects of acute stimulation of the adrenal cortex on gonadotropin
release under conditions of intact ovarian function at different cycle
phases, as well as in a setting of complete ovarian suppression. In add-
ition, given previous studies reporting an association of hormonal con-
traceptives with emotional lability, anxiety and depression (Sanders
et al., 2001; Oinonen and Mazmanian, 2002), we performed struc-
tured assessments of the psychological affective state of our study par-
ticipants in order to evaluate potential confounding effects.
Subjects andMethods
Subjects
An a priori power analysis was performed at 80% power with a signiﬁ-
cance threshold of 0.05 in order to determine the cohort sample size.
The power analysis indicated that a total sample size of 60 would pro-
vide conﬁdence to detect differences of at least medium effect size
between conditions. A total of 60 healthy women of reproductive age
participated in this study (mean 22.83, SD 3.12, range 18–30 years).
Participants were recruited through local advertisements and provided
with monetary compensation (€50) for their participation. Hormonal
contraceptive use was determined based on a structured question-
naire during the initial telephone screening and reconﬁrmed on the day
of testing. Women were considered eligible for the study only if they
met one of the following inclusion criteria for continuous hormonal
contraceptive use for at least the previous 4 months: (i) oral monopha-
sic combined preparation containing ethinylestradiol (EE) 0.03 and
0.15 mg levonorgestrel (Ethinylestradiol/levonorgestrel, Microgynon®
30 [EE30/LNG group; N = 20]), (ii) progestin-only LNG-releasing
IUD 0.02 mg/24 hours (Mirena®; Bayer [LNG-IUD group; N = 20]) or
(iii) absence of any hormonal contraceptives and having a regular men-
strual cycle length between 23 and 35 days (naturally cycling [NC]
group; N = 20). The duration of LNG-IUD use ranged from 16 to 28
months. All participants had a normal menstrual cycle length between
26 and 29 days. Exclusion criteria were a history of clinically signiﬁcant
psychiatric, neurologic, endocrine or medical illness (including alcohol
or drug dependence, asthma, allergies, cardiovascular disease, endo-
metriosis, polycystic ovary disease or gynecologic infection), body
mass index (BMI) < 19 or >26 kg/m2, atypical sleep pattern, the use
of any prescription medication other than hormonal contraceptives
within the previous 4 months and pregnancy or lactation within the
previous 12 months. Women in the EE30/LNG group were tested
during the active pill weeks. NC women were tested in the luteal
phase of the menstrual cycle, between days 20 and 27 of their cycle.
The study was conducted according to the declaration of Helsinki
and was approved by the Medical Ethical Research Committee of the
Erasmus MC, University Medical Center Rotterdam. All subjects pro-
vided written informed consent for their participation.
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Psychological assessment
To examine the possibility that responses to ACTH administration
could be confounded by differences in affect regulation between the
contraceptive groups, all participants completed the Positive and
Negative Affect Scale (PANAS), a well-validated questionnaire for meas-
uring general, positive and negative affective states (Watson et al.,
1988). Each of the 20 items is rated on a ﬁve-point Likert scale ranging
from 1 (very slightly or not at all) to 5 (extremely). The PANAS has
been established to have high reliability (positive affect scale: Cornbach’s
ɑ = 0.89, negative affect scale: ɑ = 0.85) (Watson et al., 1988).
ACTH administration
Participants abstained from smoking, alcohol, caffeinated beverages
and physical exercise on the day of testing. There were no other diet-
ary restrictions. Testing was conducted between 13.00 and 16.00
hours. The testing procedure began with a general medical examin-
ation to reconﬁrm the subject’s physical and mental health status. An
intravenous catheter was inserted either into the antecubital or the
medial cubital vein to obtain serial blood samples. The intravenous
catheter was ﬂushed with normal saline immediately after each blood
sampling time point. Following an initial 30-min rest period, baseline
venous blood samples were obtained for steroid and protein hormone
assessments (cortisol, 17-hydroxyprogesterone [17-OH-PROG],
PROG, testosterone, dehydroepiandrosterone [DHEA], androstene-
dione, dehydroepiandrosterone sulfate [DHEAS] and estradiol [E2]),
globulin levels (corticosteroid binding globulin [CBG], sex hormone
binding globulin [SHBG], LH and FSH). Immediately following with-
drawal of the baseline venous blood samples, a 1 μg intravenous bolus
of 1–24 ACTH (Synacthen®; Novartis, Basel, Switzerland) was admi-
nistered. Additional blood samples were obtained at 30 and 90
minutes following ACTH administration. Subjects were asked to sit
quietly in a semi-recumbent position throughout the entire procedure.
No adverse events were reported.
Sample collection
Blood samples were collected using Vacutainer® tubes, immediately
placed on ice upon collection and centrifuged at 4 °C for 10 minutes at
3000g within 1 hour of collection. The resulting serum was aliquoted
prior to storage at −80 °C.
Hormone determinations
With the exception of estradiol, steroid hormones were measured
using the liquid chromatography-tandem mass spectrometry method
with the CHS™ MSMS Steroids Kit (Perkin Elmer, Turku, Finland).
The Steroids Kit uses a combined solvent extraction and protein pre-
cipitation method with acetonitrile containing the deuterated internal
standards 2H5-androstenedione,
2H3-cortisol ,
2H8–17-OH-PROG,
2H6-DHEA,
2H9-PROG and
2H5-testosterone. The internal standards
undergo processing identical to the analytes. Chromatographic separ-
ation was performed on a Waters® (Milford, MA, USA) Acquity™
UPLC HSS T3 1.8 µm column (diameter 1 mm, length 10 cm) with
acetonitrile/MeOH gradient and in-line ﬁlters with 0.2 µm frits. A
Waters® XEVO-TQ-S system equipped with an electrospray ioniza-
tion (ESI) source operating in the electrospray positive mode was
used, except for DHEAS (negative ESI). Multiple reaction monitoring
was applied for the detection of the analytes using both quantiﬁers and
qualiﬁers.
The lower limits of quantiﬁcation for androstenedione, cortisol,
DHEA, DHEAS, PROG, 17-OH-PROG and testosterone were 0.20,
2.57, 2.2, 24.7, 0.13, 0.10 and 0.07 nmol/l, respectively. During the
LC-step of the steroid assay, PROG and 17-OH-PROG were com-
pletely separated, thereby removing the possibility of cross-reactivity
in this assay. Estradiol was measured by the Coat-A-Count radio-
immunoassay of Siemens Healthcare Diagnostics Products (Los
Angeles, CA, USA). Intra- and inter-assay coefﬁcients of variation for
the steroid assays were <7.0 and <8.0% for androstenedione, <6 and
<6% for cortisol, <7 and <8% for DHEA, <8 and <13% for DHEAS,
<6 and <7% for PROG, <6 and <6% for 17-OH-PROG, <6 and <9%
for testosterone and <5 and <7% for estradiol. LH, FSH and SHBG
concentrations were measured using the Siemens Immulite XPi sys-
tem. Serum CBG concentrations were determined by radioimmuno-
assay (DRG Instruments GmbH, Marburg, Germany). Intra- and inter-
assay coefﬁcients of variation were <4 and <7% for LH, <3 and 6% for
FSH, <4 and <5% for SHBG and <9 and <11% for CBG.
Data analysis
Given the inﬂuence of menstrual phase (preovulatory versus postovu-
latory) on gonadotropin release, participants from the natural cycling
and LNG-IUD groups were classiﬁed based on PROG level. Women
with PROG concentrations above 5 nmol/l were classiﬁed in the high-
PROG/high-E2 group (n = 12) and women with a lower PROG con-
centration in the low-PROG/high-E2 group (n = 28). Estradiol levels in
these two groups were not different. Women using EE30/LNG were
designated as low-PROG/low-E2 (n = 20).
Statistical analyses were conducted using the SPSS statistical soft-
ware package (IBM SPSS Statistics, Version 21). Results are expressed
as means ± SEM, unless otherwise speciﬁed. Data per parameter
were tested for normality of distribution and homogeneity of variance
using Kolmogorov–Smirnov and Levene’s tests. In six patients, one of
the hormone measurements was not possible to quantify due to inter-
fering peaks in the chromatogram (PROG: n = 1; E2: n = 1; andro-
stenedione: n = 4). To meet the normality assumption, where
necessary, hormonal data were logarithmically transformed. After log-
transformation, the data were normally distributed. In order to examine
group differences in demographic characteristics and affect, chi-squared
tests and one-way analyses of variance (ANOVAs) were conducted. To
analyze hormone proﬁles in response to ACTH administration,
ANOVAs were performed with a repeated-measure factor Time (base-
line, +30minutes, +90minutes), between-subject factor Group (low-
PROG–low-E2, low-PROG–high-E2, high-PROG–high-E2) and the
interaction effect of Time x Group. Post hoc analyses, where necessary,
were performed using Bonferroni multiple means comparisons. To
reduce the possibility of a Type I error when analyzing steroid reactivity,
statistical signiﬁcance for these tests was deﬁned at the more stringent
threshold of P < 0.01. In order to check for potentially confounding
effects of age, BMI and PANAS scores on the steroid and gonadotropin
responses, these parameters were ﬁrst evaluated separately in a set of
ANOVAs for repeated measures. Age, BMI and PANAS scores did not
yield signiﬁcant main or interaction effects in relation to the steroid or
gonadotropin responses. Therefore, these variables were not included
as covariates in subsequent analyses.
2362 Aleknaviciute et al.
 at Erasm
us U
niversiteit Rotterdam
 on N
ovem
ber 7, 2016
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
Since EE inﬂuences levels of CBG, which binds cortisol with high
afﬁnity, CBG concentrations were included as covariates in analyses of
cortisol concentrations. For general linear models, F-values, degrees of
freedom and P-values were corrected by the Greenhouse-Geisser pro-
cedure whenever the assumption of sphericity was violated. Effect
sizes were calculated by partial eta squared (η2). P-values <0.01 were
considered to be statistically signiﬁcant.
Results
Subject characteristics, and baseline ACTH
and binding globulin levels
The groups did not differ signiﬁcantly in age or BMI (Table I). No sig-
niﬁcant differences were found in positive or negative affect scores
on the PANAS, indicating comparable baseline affective states
between the study groups (Table I). The study groups were also
similar in their baseline ACTH levels (Table I). Importantly, how-
ever, the low-PROG–low-E2 group exhibited signiﬁcantly higher
baseline CBG (P < 0.001) and SHBG levels (P < 0.001), due to the
stimulating effect of the synthetic estrogen in the oral contraceptive
(Table I).
Effect of ACTH administration on
gonadotropin release
ACTH administration resulted in signiﬁcant time-dependent changes
of LH and FSH levels in all groups (low-PROG–high-E2 and high-
PROG–high-E2, P < 0.001; low-PROG–low-E2, P < 0.05). The groups
differed signiﬁcantly regarding LH levels, with the low-PROG–low-E2
group displaying overall lower LH concentrations (P < 0.001; post hoc:
low-PROG–high-E2 = high-PROG–high-E2 > low-PROG–low-E2;
Fig. 1a). No signiﬁcant Group × Time interaction effect was observed.
The FSH levels differed signiﬁcantly between the study groups
(P < 0.001). A signiﬁcant Group x Time interaction was observed
(P < 0.05; post hoc: low-PROG–high-E2 > high-PROG–high-
E2 > low-PROG–low-E2; Fig. 1b); the EE30/LNG group displayed a
blunted FSH response to ACTH administration (P < 0.01).
Effects of ACTH administration on the
steroid proﬁle
ACTH administration resulted in signiﬁcant time-dependent changes in
the levels of cortisol, 17-OH-PROG, PROG, testosterone, DHEA,
DHEAS and androstenedione (P < 0.001 for each group × steroid
combination), all displaying signiﬁcant increases at 30 minutes after
ACTH administration (P < 0.01 for each group × steroid combin-
ation). With regard to E2, a signiﬁcant increase was observed 90
minutes after ACTH administration in the low-PROG–high-E2 and
high-PROG–high-E2 groups (P < 0.001 for each group), but no change
was found in the low-PROG–low-E2 group.
Cortisol
The study groups differed signiﬁcantly with regard to total serum corti-
sol levels. Women using oral contraceptives (low-PROG–low-E2
group) exhibited signiﬁcantly higher mean total cortisol levels, com-
pared to the low-PROG–high-E2 and high-PROG–high-E2 groups
(P < 0.001; Fig. 2a). However, after controlling for CBG levels, no sig-
niﬁcant group or interaction effect remained, conﬁrming the inﬂuence
of CBG on cortisol levels.
Progesterone
The study groups differed signiﬁcantly regarding PROG levels, with the
high-PROG–high-E2 group showing higher overall PROG than the
low-PROG–high-E2 and low-PROG–low-E2 groups (P < 0.001).
ACTH administration induced a signiﬁcant increase in PROG in the
low-PROG–high-E2 and low-PROG–low-E2 groups, but not in the
high-PROG–high-E2 group (P < 0.001; Fig. 2b).
17-OH-PROG
17-OH-PROG levels differed signiﬁcantly between the study groups at
baseline, +30 and +90 minutes post-ACTH administration (P < 0.001;
post hoc: high-PROG–high-E2 > low-PROG–high-E2 > low-PROG–
low-E2). Furthermore, a signiﬁcant Group × Time interaction effect
was observed (P < 0.001), with the low-PROG–low-E2 group display-
ing relatively higher 17-OH-PROG increases at 30 minutes post-
ACTH administration compared to the high-PROG–high-E2 and low-
PROG–high-E2 groups (Table II).
.............................................................................................................................................................................................
Table I Subject characteristics, affect state and baseline globulin and ACTH levels of the experimental groups.
low-PROG/ high-E2 high-PROG/ high-E2 low-PROG/ low-E2
(n = 28) (n = 12) (n = 20)
Age, mean (SD), years 23.04 (3.26) 23.42 (4.64) 22.2 (1.47)
BMI, mean (SD), kg/m2 22.16 (2.11) 21.87 (1.30) 22.53 (2.89)
PANAS
Positive affect scale, mean (SD), score 28.14 (5.82) 28.58 (3.87) 29.45 (6.89)
Negative affect scale, mean (SD), score 13.75 (3.23) 13.17 (2.73) 12.00 (2.15)
SHBG, mean (SD), µg/ml 25.76 (8.53) 26.41 (8.94) 50.94 (14.69)a
ACTH, mean (SD), µg/ml 3.40 (1.37) 2.03 (1.07) 3.07 (3.35)
CBG, mean (SD), µg/ml 52.91 (8.60) 57.08 (6.11) 120.99 (22.11)a
PANAS, positive affect and negative affect scale; CBG, corticosteroid binding globulin; SHGB, sex hormone binding globulin; ACTH, adrenocorticotropic hormone.
aOne-way analysis of variance between three experimental groups, P < 0.001.
2363ACTH challenge elicits gonadotropin secretion
 at Erasm
us U
niversiteit Rotterdam
 on N
ovem
ber 7, 2016
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
Androstenedione
Androstenedione levels differed signiﬁcantly between the groups
(P < 0.001; post hoc: high-PROG–high-E2 = low-PROG–high-
E2 > low-PROG–low-E2), with the low-PROG–low-E2 group displaying
overall lower androstenedione levels, compared to the high-PROG–
high-E2 and low-PROG–high-E2 groups (Table II). No signiﬁcant
Group × Time interaction effect was observed.
Dehydroepiandrosterone
The study groups differed signiﬁcantly in DHEA concentrations at
baseline, and +30 and +90 minutes post-ACTH administration
(P < 0.001; post hoc: high-PROG–high-E2 = low-PROG–high-
E2 > low-PROG–low-E2; Table II). No signiﬁcant Group × Time inter-
action effect was observed.
Dehydroepiandrosterone sulfate
DHEAS levels differed signiﬁcantly between the study groups
(P < 0.01; post hoc: high-PROG–high-E2 = low-PROG–high-
E2 > low-PROG–low-E2), with the high-PROG–high-E2 and low-
PROG–high-E2 groups displaying higher overall levels when compared
to the low-PROG–low-E2 group (Table II). No signiﬁcant Group ×
Time interaction effect was observed.
Testosterone
The low-PROG–low-E2 group exhibited overall lower testosterone
levels, compared to the high-PROG–high-E2 and low-PROG–high-E2
groups (P < 0.001; Table II). A signiﬁcant Group × Time interaction
effect demonstrated a larger increase of testosterone levels following
ACTH administration in the low-PROG–low-E2 group, compared to
the high-PROG–high-E2 and low-PROG–high-E2 groups (P < 0.01).
Estradiol
E2 levels were signiﬁcantly different between the study groups: the
low-PROG–low-E2 group had lower E2 levels than the high-PROG–
high-E2 and low-PROG–high-E2 groups (P < 0.001). No differences
were observed in E2 levels between the high-PROG–high-E2 and low-
PROG–high-E2 groups. ACTH administration induced a signiﬁcant
increase of E2 in the high-PROG–high-E2 and low-PROG–high-E2
groups, but not in low-PROG–low-E2 users (P < 0.001; post hoc:
NC = LNG-IUD > EE30/LNG; Fig. 2c).
Discussion
The aim of our study was to examine the inﬂuence of acute adrenal
cortex stimulation on gonadotropin release in three groups of preme-
nopausal women distinguished by the different levels of PROG and
estradiol: high-PROG–high-E2, low-PROG–high-E2 and low-PROG–
low-E2. Basal hormone levels differed between groups on the basis of
cycle phase (PROG and 17-OH-PROG in the high-PROG–high-E2 and
low-PROG–high-E2 groups), and on the basis of suppression of LH
and FSH in the female group using oral contraceptives, with low-
PROG–low-E2 leading to suppression of the ovarian component of
the production of androgens and estradiol.
Steroid-dependent regulation of gonadotropin release has been
shown to involve a complex interaction with estrogen, as observed in
studies of estrogen-replacement therapy in postmenopausal women,
in which activation of the HPA axis resulted in gonadotropin release
only in the presence of sufﬁcient levels of circulating estrogen (Puder
et al., 2000). In our study, estrogens were present in all study groups:
endogenous estradiol in the high-PROG–high-E2 and low-PROG–
high-E2 groups, and EE in the low-PROG–low-E2 group. Further
(a) (b)
Figure 1 Untransformed raw LH (a) and FSH (b) mean ± SEM values at baseline, +30 and +90 minutes after administration of low-dose (1 µg) adre-
nocorticotropic hormone (ACTH). ACTH was administered in three experimental hormonal-based populations: low-PROG–low-E2, low-PROG–
high-E2 and high-PROG–high-E2. ACTH administration resulted in signiﬁcant time-dependent changes of LH and FSH levels in all groups (low-PROG–
high-E2 and high-PROG–high-E2, P < 0.001; low-PROG–low-E2, P < 0.05). (a) The groups differed signiﬁcantly regarding LH levels, with the low-
PROG–low-E2 group displaying overall lower LH concentrations (P < 0.001). No signiﬁcant interaction effects were found. (b) The FSH levels differed
signiﬁcantly between the study groups (P < 0.001, post hoc: low-PROG–high-E2 > high-PROG–high-E2 > low-PROG–low-E2). A signiﬁcant Group ×
Time interaction was observed (P < 0.02); the low-PROG–low-E2 group displayed a blunted FSH response to ACTH administration (P < 0.01).
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evidence that adrenal steroid secretion is associated with gonado-
tropin release comes from animal studies in which adrenalectomy and
pretreatment with RU486, which has antiglucocorticoid and anti-
PROG activities, each abolished stress-induced gonadotropin release
(Putnam et al., 1991; Xiao et al., 1994, Zalanyi, 2001). Similar to the
results of human studies, the stimulatory effect of ACTH was
observed only in estrogen-primed rats, consistent with the essential
requirement of adequate estradiol (Putnam et al., 1991; Mahesh and
Brann, 1998).
In our data, a signiﬁcant increase in ACTH-induced gonadotropin
levels was observed in all groups. Among women with low levels of
PROG, ACTH administration led to increased PROG in the presence
of normal estradiol levels. This permissive hormonal context is com-
parable to that in the beginning of the midcycle peak of LH and FSH
(Hoff et al., 1983). Earlier research has established that estradiol and
PROG inﬂuence the induction of the midcycle gonadotropin surge
(Young and Jaffe, 1976; Terasawa et al., 1980). In our study, adrenal
stimulation by ACTH caused a near doubling of the relatively low-
PROG levels in the low-PROG–high-E2 and low-PROG–low-E2
groups. However, in the high-PROG–high-E2 group, in which estradiol
levels were comparable to those in the low-PROG–high-E2 group, a
similar increase in gonadotropin levels was observed in the absence of
(a)
(c)
(b)
Figure 2 Untransformed raw cortisol (a), progesterone (b) and estradiol (c) mean ± SEM values at baseline, +30 and +90 minutes after administra-
tion of low-dose (1 µg) ACTH. ACTH was administered in three experimental hormonal-based populations: low-PROG–low-E2, low-PROG–high-E2
and high-PROG–high-E2. (a) The study groups differed signiﬁcantly with regard to total serum cortisol levels. Women using EE30/LNG (low-PROG–
low-E2) exhibited signiﬁcantly higher mean total cortisol levels, compared to the low-PROG–high-E2 and high-PROG–high-E2 groups (P < 0.001).
However, after controlling for CBG levels, no signiﬁcant group or interaction effect remained. (b) ACTH administration induced a signiﬁcant increase in
PROG in the low-PROG–high-E2 and low-PROG–low-E2 groups, an effect that was not observed in the high-PROG–high-E2 group (P < 0.001). (c)
The low-PROG–low-E2 group had lower E2 levels than the low-PROG–high-E2 and high-PROG–high-E2 groups (P < 0.001). ACTH administration
induced a signiﬁcant increase in E2 in the low-PROG–high-E2 and high-PROG–high-E2 groups, but not in the low-PROG–low-E2 group (P < 0.001).
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increased PROG levels. Therefore, the analogous ACTH effects on
gonadotropin release in the high-PROG–high-E2 and low-PROG–high-
E2 groups suggests that PROG is unlikely to be mediating the increase
in LH and FSH.
Alternative mechanisms to explain the ACTH-induced release of LH
and FSH might involve the inﬂuence of 17-OH-PROG, androgens,
estradiol or cortisol. In our study, the relative effect of ACTH on circu-
lating levels of 17-OH-PROG was even larger than observed for
PROG, in accordance with previous studies (De Geyter et al., 2002).
Elevated levels of 17-OH-PROG are in line with earlier reports show-
ing that peripheral levels of 17-OH-PROG during the luteal phase of
the cycle are higher than those during the follicular phase (Aedo et al.,
1981). It has recently been described that 17-OH-PROG may have
glucocorticoid activity due to its binding to the glucocorticoid receptor
(GR) and its ability to transactivate the GR in vitro (Pijnenburg-Kleizen
et al., 2015). However, considering that 17-OH-PROG binds weakly
to the GR and is a less potent agonist of GR than cortisol, it is unlikely
that the observed gonadotropin increase in our study is mediated by
17-OH-PROG (Pijnenburg-Kleizen et al., 2015). Furthermore,
although earlier research in rhesus monkeys has suggested that 17-
OH-PROG may facilitate the onset of LH surges (Schenken et al.,
1985), the stimulating effect of 17-OH-PROG on LH release was not
found in humans (Leyendecker et al., 1976). This makes it unlikely that
the increase of 17-OH-PROG caused the surge of gonadotropins.
Regarding the inﬂuence of increased levels of androgens and estra-
diol in the ACTH-induced release of gonadotropins, it is very unlikely
that these steroids function prominently since only suppressive effects
of androgens have been described in patients with androgen-
.............................................................................................................................................................................................
Table II Adrenal steroid levels in response to ACTH stimulation in the experimental groups.
low-PROG/high-E2 high-PROG/high-E2 low-PROG/low-E2 P-value within group P-value between group
Cortisol (nmol/l) n = 28 n = 12 n = 20
Baseline 182.58 (89.16) 158.82 (41.55) 386.60 (116.99) <0.001 <0.001
30 minutes 435.73 (61.28) 456.86 (77.89) 791.81 (183.24)
90 minutes 261.26 (56.25) 295.48 (65.88) 612.08 (176.64)
Progesterone (nmol/l) n = 28 n = 11 n = 20
Baseline 0.63 (0.50) 25.71 (16.88) 0.19 (0.06) <0.001 <0.001
30 minutes 0.93 (0.68) 20.53 (12.77) 0.55 (0.25)
90 minutes 0.81 (0.78) 24.06 (14.45) 0.28 (0.09)
17-OH Progesterone (nmol/l) n = 28 n = 12 n = 20
Baseline 1.25 (0.76) 4.35 (1.89) 0.19 (0.13) <0.001 <0.001
30 minutes 2.39 (0.98) 5.79 (2.69) 1.49 (0.71)
90 minutes 1.41 (0.69) 4.38 (1.90) 0.39 (0.21)
Androstenedione (nmol/l) n = 27 n = 12 n = 17
Baseline 4.01 (1.70) 3.90 (1.48) 1.73 (0.71) <0.001 <0.001
30 minutes 5.48 (2.27) 5.51 (1.33) 2.61 (0.84)
90 minutes 4.16 (1.61) 4.01 (1.20) 1.92 (0.63)
DHEA (nmol/l) n = 28 n = 12 n = 20
Baseline 21.50 (10.43) 16.84 (5.48) 11.18 (4.91) <0.001 <0.001
30 minutes 43.73 (15.95) 45.31 (12.90) 24.52 (10.73)
90 minutes 21.25 (8.57) 20.52 (7.48) 11.85 (3.87)
DHEAS (µmol/l) n = 28 n = 12 n = 20
Baseline 5.15 (2.43) 6.06 (2.73) 4.10 (1.69) <0.01 0.02
30 minutes 5.34 (2.53) 5.87 (2.16) 4.21 (1.68)
90 minutes 5.15 (2.29) 5.97 (2.31) 4.06 (1.66)
Testosterone (nmol/l) n = 28 n = 12 n = 20
Baseline 0.97 (0.36) 1.04 (0.45) 0.55 (0.18) <0.001 <0.001
30 minutes 1.11 (0.36) 1.13 (0.36) 0.70 (0.23)
90 minutes 1.08 (0.40) 1.10 (0.41) 0.58 (0.17)
E2 (pmol/l) n = 27 n = 12 n = 20
Baseline 253.96 (197.80) 304.27 (106.38) 39.44 (15.97) <0.001 <0.001
30 minutes 243.00 (181.95) 292.58 (103.17) 34.71 (17.47)
90 minutes 324.45 (244.79) 348.72 (136.16) 37.80 (18.49)
Data are presented as mean ± SD. DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate.
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producing tumors (Gabrilove et al., 1981; Jarabak and Talerman,
1983) or in rats (Clayton, 1993). Moreover, the increase in estradiol
levels was detectable only 90 minutes after the administration of
ACTH, whereas the surge of LH and FSH was already evident after
30 minutes.
Taken together, we believe that cortisol is the most parsimonious
mediator of the increased levels of LH and FSH after ACTH injection.
This is in accordance with the results of experiments in rats, in which
glucocorticoids have been shown to affect gonadotropin release via
receptor-mediated mechanisms (Briski, 1996), and for which GR activ-
ity has been shown to modulate LH through both pituitary and neu-
roendocrine mechanisms following exposure to stress (Siegel et al.,
1981; Armario et al., 1986; Lopez-Calderon et al., 1990).
This study has several limitations. Because this is a secondary data
analysis, examining the impact of acute adrenal stimulation on gonado-
tropin release was not the primary goal when designing the original
study. Therefore, women having a natural menstrual cycle were tested
during their luteal phase. Testing during the follicular phase of the men-
strual cycle might have elicited premature, or more pronounced, LH
surges in response to ACTH administration. However, reclassiﬁcation
of our data based on different PROG levels, despite similar estradiol
concentrations, did not change the ﬁndings. Additionally, women were
not randomly assigned to the study, but were recruited based on their
use of contraceptives. However, the groups were very similar for all
known confounding variables, including general medical health, age,
BMI, and affective state.
While it is likely that the increase in gonadotropins observed in this
study is due to a mediating effect of cortisol, it is also possible that
administration of ACTH might have resulted in downstream adapta-
tions to corticotropin-releasing hormone through a secondary feed-
back loop. However, the low-dose (1 μg) ACTH stimulation test has
been well documented to be more physiological and sensitive than, for
example, higher dose (250 μg or 100 μg) ACTH stimulation tests. The
1 μg low-dose administration results in a maximal serum ACTH con-
centration of 200 ng/l, which is of a similar order of magnitude to that
observed in venous blood samples from the sinus petrosus inferior
(W. W. de Herder, unpublished results). Therefore, it seems unlikely
that a 1 μg dose of ACTH directly affects pituitary function additionally
because the extensive literature of investigations using the same low-
dose ACTH formulation has never previously reported direct alter-
ation of pituitary function. Furthermore, we acknowledge the lack of
prolactin measurements that might have provided better insight into
the stress-induced gonadotropin release. However, considering that
prolactin is released from the anterior pituitary and our focus was on
the effects of adrenal stimulation, we considered the effect of prolactin
to be negligible.
In conclusion, our data are the ﬁrst to demonstrate that acute stimu-
lation of adrenal steroid production, most likely cortisol, mediates
enhanced gonadotropin release in healthy premenopausal women.
More generally, these ﬁndings contribute to an improved understand-
ing of the inﬂuence of acute stress on reproductive endocrinology.
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